Jocelyn Sendecki
Overview
Explore the profile of Jocelyn Sendecki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
625
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eyerich K, Asadullah K, Pinter A, Weisenseel P, Reich K, Paul C, et al.
JAMA Dermatol
. 2024 Jul;
160(9):953-963.
PMID: 39083288
Importance: Psoriasis is a chronic inflammatory skin disease with unmet needs for tailored treatment and therapy de-escalation strategies. Objective: To evaluate early intervention with and prolonging the dosing interval for...
2.
Potter D, Bradstreet T, Sargsyan D, Tan X, Bonato V, Li D, et al.
Pharm Stat
. 2024 Jun;
24(1):e2390.
PMID: 38860641
In this tutorial we explore the valuable partnership between statisticians and Institutional Animal Care and Use Committees (IACUCs) in the context of animal research, shedding light on the critical role...
3.
Lin C, Duan Y, Sargsyan D, Geys H, Sendecki J, Tatikola K, et al.
J Biopharm Stat
. 2024 Jun;
:1-7.
PMID: 38836424
A complete workflow was presented for estimating the concentration of microorganisms in biological samples by automatically counting spots that represent viral plaque forming units (PFU) bacterial colony forming units (CFU),...
4.
DeAngelis N, Ferrante C, Powers G, Sendecki J, Mattson B, Pizutti D, et al.
Cancer Chemother Pharmacol
. 2022 Mar;
89(4):515-527.
PMID: 35298699
Purpose: Preclinical characterization of cetrelimab (JNJ-63723283), a fully humanized immunoglobulin G4 kappa monoclonal antibody targeting programmed cell death protein-1 (PD-1), in human cancer models. Methods: Cetrelimab was generated by phage...
5.
Verkleij C, Broekmans M, van Duin M, Frerichs K, Kuiper R, de Jonge A, et al.
Blood Adv
. 2021 Apr;
5(8):2196-2215.
PMID: 33890981
Cell surface expression levels of GPRC5D, an orphan G protein-coupled receptor, are significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or other immune cells, which renders...
6.
Kinder M, Bahlis N, Malavasi F, De Goeij B, Babich A, Sendecki J, et al.
Haematologica
. 2021 Jan;
106(7):2004-2008.
PMID: 33440920
No abstract available.
7.
Vijayaraghavan S, Lipfert L, Chevalier K, Bushey B, Henley B, Lenhart R, et al.
Mol Cancer Ther
. 2020 Aug;
19(10):2044-2056.
PMID: 32747419
Small molecule inhibitors targeting mutant EGFR are standard of care in non-small cell lung cancer (NSCLC), but acquired resistance invariably develops through mutations in EGFR or through activation of compensatory...
8.
Nair-Gupta P, Diem M, Reeves D, Wang W, Schulingkamp R, Sproesser K, et al.
Blood Adv
. 2020 Mar;
4(5):906-919.
PMID: 32150609
CD33 is expressed in 90% of patients with acute myeloid leukemia (AML), and its extracellular portion consists of a V domain and a C2 domain. A recent study showed that...
9.
Frerichs K, Broekmans M, Marin Soto J, van Kessel B, Heymans M, Holthof L, et al.
Clin Cancer Res
. 2020 Jan;
26(9):2203-2215.
PMID: 31969333
Purpose: Multiple myeloma (MM) patients with disease refractory to all available drugs have a poor outcome, indicating the need for new agents with novel mechanisms of action. Experimental Design: We...
10.
Peters L, Perrigoue J, Mortha A, Iuga A, Song W, Neiman E, et al.
Nat Genet
. 2017 Sep;
49(10):1437-1449.
PMID: 28892060
A major challenge in inflammatory bowel disease (IBD) is the integration of diverse IBD data sets to construct predictive models of IBD. We present a predictive model of the immune...